Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.82 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 4/20 | 0.74 |
| ▸ | IGF1R | P08069 | 1/20 | 0.73 |
| ▸ | PIM1 | P11309 | 1/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.71 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.71 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.71 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.71 |
| ▸ | MGAM | O43451 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | SI | P14410 | 1/20 | 0.67 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508719 | 1.00 | MEN1 (1.00) | MEN1KMT2ACISD1PTPN1HPGD | |
| SCHEMBL1249272 | 0.93 | MEN1 (0.87) | MEN1KMT2ACISD1PTPN1HPGD | |
| SCHEMBL1249271 | 0.93 | MEN1 (0.87) | MEN1KMT2ACISD1PTPN1HPGD | |
| SCHEMBL21263140 | 0.90 | CISD1 (1.00) | MEN1KMT2ACISD1HPGDPDE4B | |
| SCHEMBL1609551 | 0.90 | CISD1 (1.00) | MEN1KMT2ACISD1HPGDPDE4B | |
| SCHEMBL8187177 | 0.89 | MEN1 (0.80) | MEN1KMT2ACISD1PTPN1HPGD | |
| SCHEMBL8187176 | 0.89 | MEN1 (0.80) | MEN1KMT2ACISD1PTPN1HPGD | |
| SCHEMBL5504181 | 0.88 | MEN1 (0.79) | MEN1KMT2ACISD1PTPN1HPGD | |
| SCHEMBL5504182 | 0.88 | MEN1 (0.79) | MEN1KMT2ACISD1PTPN1HPGD | |
| SCHEMBL1300032 | 0.85 | HPGD (1.00) | MEN1KMT2ACISD1PTPN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | claimed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | claimed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | claimed |
| EP-1781271-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006019741-A1 | ARYLIDENES FOR THE TREATMENT OF ESTROGEN RELATED RECEPTOR-ALPHA MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-19 | — | — | US | disclosed |
| WO-2000018746-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014812-A1 | Use of estrogen related receptor-modulating aryl ethers | ESR2, ESRRG, GPER1 | MEN1 4702/4885KMT2A 1285/4885CISD1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.